Showing results (11-20 of 3,590) with videos related to
Sort By:
Pageof 359
Molecular Medicine (Cambridge, Mass.)|November 20, 2001
Systemic p53 gene therapy of cancer with immunolipoplexes targeted by anti-transferrin receptor scFvL Xu, W H Tang, C C Huang, et al.Radiation Research|November 1, 1993
Cytogenetic response to G2-phase X irradiation in relation to DNA repair and radiosensitivity in a cancer-prone family with Li-Fraumeni syndromeR Parshad, F M Price, K F Pirollo, et al.British Journal of Cancer|January 1, 1991
Aberrant DNA topoisomerase II activity, radioresistance and inherited susceptibility to cancerJ M Cunningham, G E Francis, M J Holland, et al.Cancer Gene Therapy|November 1, 2001
Inhibitory effects of the combination of HER-2 antisense oligonucleotide and chemotherapeutic agents used for the treatment of human breast cancerA S Rait, K F Pirollo, V Rait, et al.International Journal of Radiation Biology|May 1, 1989
raf involvement in the simultaneous genetic transfer of the radioresistant and transforming phenotypesK F Pirollo, R Garner, S Y Yuan, et al.Carcinogenesis|July 1, 1992
The status of the p53 gene in human papilloma virus positive or negative cervical carcinoma cell linesS Srivastava, Y A Tong, K Devadas, et al.Biochemistry|August 27, 1991
Antisense inhibition of ras p21 expression that is sensitive to a point mutationE H Chang, P S Miller, C Cushman, et al.Oncogene|April 10, 1997
p53 mediated sensitization of squamous cell carcinoma of the head and neck to radiotherapyK F Pirollo, Z Hao, A Rait, et al.Journal of Experimental Pathology|January 1, 1985
Pathogenicity of retroviruses containing either the normal human c-Ha-ras1 gene or its mutated form derived from the bladder carcinoma EJ/T24 cell lineE H Chang, P L Morgan, E J Lee, et al.Nanotechnology|August 11, 2011
Physical characterization methods for iron oxide contrast agents encapsulated within a targeted liposome-based delivery systemJ A Dagata, N Farkas, C L Dennis, et al.Pageof 359